Pacific Biosciences of California, Inc. (PACB) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PACB Revenue Growth
Revenue Breakdown (FY 2025)
PACB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PACB Revenue Analysis (2014–2025)
As of May 8, 2026, Pacific Biosciences of California, Inc. (PACB) generated trailing twelve-month (TTM) revenue of $160.0 million, reflecting strong growth of +13.8% year-over-year. The most recent quarter (Q4 2025) recorded $44.6 million in revenue, up 16.1% sequentially.
Looking at the longer-term picture, PACB's 5-year compound annual growth rate (CAGR) stands at +15.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $200.5 million in 2023.
Revenue diversification analysis shows PACB's business is primarily driven by Product (46%), Consumable (28%), and Instrument (18%).
When compared to Healthcare sector peers including ILMN (+1.2% YoY), BFLY (+20.2% YoY), and CDNA (+19.2% YoY), PACB has underperformed the peer group in terms of revenue growth. Compare PACB vs ILMN →
PACB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PACBCurrent | $160M | +13.8% | +15.2% | -348.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 BFLY | $98M | +20.2% | +16.1% | -88.5% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 TMO | $44.6B | +5.4% | +6.7% | 18.2% | |
 DHR | $24.6B | +4.0% | +2.0% | 20.9% |
PACB Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $160.0M | +3.9% | $50.7M | 31.7% | $-557,561,000 | -348.5% |
| 2024 | $154.0M | -23.2% | $37.3M | 24.2% | $-474,313,000 | -308.0% |
| 2023 | $200.5M | +56.3% | $52.8M | 26.3% | $-334,467,000 | -166.8% |
| 2022 | $128.3M | -1.7% | $49.0M | 38.2% | $-307,196,000 | -239.4% |
| 2021 | $130.5M | +65.4% | $58.9M | 45.1% | $-210,435,000 | -161.2% |
| 2020 | $78.9M | -13.2% | $32.6M | 41.3% | $-104,385,000 | -132.3% |
| 2019 | $90.9M | +15.6% | $34.6M | 38.0% | $-100,545,000 | -110.6% |
| 2018 | $78.6M | -15.9% | $25.1M | 31.9% | $-100,987,000 | -128.4% |
| 2017 | $93.5M | +3.0% | $34.7M | 37.1% | $-89,784,000 | -96.1% |
| 2016 | $90.7M | -2.2% | $44.2M | 48.7% | $-71,244,000 | -78.5% |
See PACB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PACB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PACB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPACB — Frequently Asked Questions
Quick answers to the most common questions about buying PACB stock.
Is PACB's revenue growth accelerating or slowing?
PACB maintains +13.8% revenue growth, in line with its 5-year CAGR of +15.2%. TTM revenue stands at $160M. Growth rate remains consistent with historical average.
What is PACB's long-term revenue growth rate?
Pacific Biosciences of California, Inc.'s 5-year revenue CAGR of +15.2% reflects the sustained expansion pattern. Current YoY growth of +13.8% is near this long-term average.
How is PACB's revenue distributed by segment?
PACB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.